Sensus Blog

The future of skin cancer treatment is now. Stay ahead of the curve with our library of informational blogs.

April
27
2026

Basal Cell Carcinoma vs. Squamous Cell Carcinoma: What’s the Difference?

Melanoma and non-melanoma are two primary categories of skin cancer. Each presents different symptoms and treatment options. Within the non-melanoma skin cancer – sometimes referred to as NMSC – category, the two most common types…

September
23
2025

Study Published in Dermatologic Therapy Shows Efficacy of Sensus Healthcare’s SRT Combined with Punch Excision to Treat Keloids

BOCA RATON, Fla. – Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces that a study published in Dermatologic…

August
31
2025

Skin Care Awareness Month: Why Early Detection and Non-Invasive Treatments Matter

September is Skin Care Awareness Month, which is an important time to reflect on the role skin health plays in overall well-being. Skin is the body’s largest organ, serving as the first line of defense…

August
30
2025

Understanding Superficial Radiotherapy: A Patient-Centered Approach to Skin Cancer Treatment

Superficial Radiotherapy (SRT) is a safe and effective treatment option for many patients experiencing non-melanoma skin cancers, like basal cell carcinoma and squamous cell carcinoma. Patients often find its less invasive nature an appealing alternative…

August
07
2025

Sensus Healthcare Reports Second Quarter 2025 Financial Results

Shipped 19 SRT systems during the quarter, including four to China Revenues of $7.3 million FDA treatment volume increased 27% over the first quarter Exited the quarter with $22.2 million in cash and no debt…

Archives
Archives

IN THE NEWS

CEO Joseph Sardano on Coding for Superficial Radiation Therapy